Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma: An Analysis of the CARTITUDE-4 Trial.
CAR-T cell therapy for hard-to-treat myeloma provides good value compared to standard care, supporting insurance coverage for more patients earlier.
This economic analysis using Phase III CARTITUDE-4 trial data demonstrates that ciltacabtagene autoleucel is cost-effective compared to standard of care in lenalidomide-refractory multiple myeloma. The findings support broader payer consideration of cilta-cel in earlier lines of MM treatment.
What the study was
- Study design
- Cost-effectiveness analysis (Phase III RCT data, CARTITUDE-4)
- Population
- Lenalidomide-refractory multiple myeloma patients
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Why it surfaced
Phase III cost-effectiveness data for a transformative CAR-T therapy in relapsed/refractory multiple myeloma; directly informs coverage decisions and clinical adoption.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.